Douglas Galasko on Serum NfL Detects Preclinical AD, Reflects Clinical Benefit
COMMENT The study of NfL in autosomal-dominant AD (ADAD) provides exciting preliminary evidence supporting this as a progression marker. The effect size was much more impressive in symptomatic patients than in preclinical carriers, and it will be interesting to s